arrow
P

Peter Mazal

Medical University of Vienna
H指数:29
被引数:3,234

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial

PSMA导向的PET/MRI可在PSA水平升高的患者中实现非侵入性诊断和预后评估:来自前瞻性随机RAPID试验的结果

2026-02-011
PRE
Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients

诊断前的转移性疾病和主要不良心血管事件是嗜铬细胞瘤/副神经节瘤疾病特异性生存的主要决定因素: 303例患者的长期随访

2024-08-210
OAAI
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

去势抵抗性前列腺癌患者的单病灶前列腺特异性膜抗原蛋白表达 (PSMA) 和对 [177Lu]-PSMA配体治疗的反应

2021-08-016
OAAI
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI

监督机器学习可通过 [68Ga]Ga-PSMA-11 PET/MRI实现原发性前列腺癌的非侵入性病变表征

2020-12-1990
OAAI
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact

PSMA配体PET/MRI对原发性前列腺癌的分期表现和临床影响

2018-12-13118
OAAI
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making

前列腺癌根治术后生化复发患者的68Ga-PSMA 11配体PET成像-诊断性能和对治疗决策的影响

2017-10-2695
OAAI